During the past decade, GU Research Network / Urology Cancer Center conducted 61 clinical trials. In the 10-year time frame, 61 clinical trials started and 32 clinical trials were completed, i.e. on average, 52.5% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 20 clinical trials were completed. i.e. 87% of trials that started reached the finish line.

Out of the total clinical trials conducted in "GU Research Network / Urology Cancer Center" #1 sponsor was "Dendreon" with 5 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "National Cancer Institute (NCI)" with 5 trials sponsored, "Pfizer" with 5 trials sponsored and "Bristol-Myers Squibb" with 5 trials sponsored. Other sponsors include 56 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "GU Research Network / Urology Cancer Center" #1 collaborator was "Astellas Pharma Inc" with 4 trials as a collaborator, "Bayer" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 3 trials as a collaborator and "Foundation Medicine" with 2 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "GU Research Network / Urology Cancer Center" are "Prostate Cancer" (22 trials), "Prostatic Neoplasms" (7 trials), "Prostate Cancer Metastatic" (5 trials), "Castration-resistant Prostate Cancer" (3 trials) and "Metastatic Castration Resistant Prostate Cancer" (3 trials). Many other conditions were trialed in "GU Research Network / Urology Cancer Center" in a lesser frequency.

Most popular intervention types in "GU Research Network / Urology Cancer Center" are "Drug" (71 trials), "Biological" (18 trials), "Other" (14 trials), "Radiation" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Enzalutamide" (8 trials), "Nivolumab" (6 trials), "Docetaxel" (5 trials) and "Prednisone" (5 trials). Other intervention names were less common.

The vast majority of trials in "GU Research Network / Urology Cancer Center" are 61 trials for "Male" genders, 21 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are 42 active trials in "GU Research Network / Urology Cancer Center". 1 are not yet recruiting, 19 are recruiting, 21 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 34 completed trials in GU Research Network / Urology Cancer Center, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in GU Research Network / Urology Cancer Center, 18 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".